A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT07013435
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Health Education Program — OTHER8 weekly sessions that include education on the co-occurrence of mental and physical problems, goal setting for health behavior change, and self-monitoring. Each session includes basic didactic information, interactive application of the information, and open discussion of didactic material.
- SMART3RP-Lymphoma — OTHERThe SMART3RP-lymphoma is a group program that, through a variety of mind-body approaches, such as imagery, relaxation, and yoga, seeks to buffer stress and promote psychological resiliency and physical well-being.
Study Details
The goal of this trial is to learn if a resilience intervention can lead to improvements in lymphoma survivors' quality of life.
Key Dates
- Start date
- May 31, 2026
- Status verified
- Jun 2025
- Primary completion
- Jan 31, 2029
- Completion
- Jan 31, 2030
Study Design
- Enrollment
- 254 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Active Comparator: Health Education ProgramParticipants will participate in 8 weekly sessions. Components include: * education on the co-occurrence of mental and physical problems * goal setting for health behavior change * self-monitoring HEP is an active control condition for mind body programs and is structurally equivalent to SMART3RP
- Experimental: SMART3RP-LymphomaParticipants will participate in 8 weekly sessions. The intervention components include: * Eliciting the relaxation response (RR), * CBT strategies to improve stress management * Positive psychology strategies to achieve growth enhancement
Primary Outcome Measure
Quality of Life (QoL): Change in PROMIS-29 [ Time Frame: From enrollment to 6 month follow up ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mass General Hospital | Boston | Massachusetts | 02114 | Giselle K Perez, PhD Giselle K Perez, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
By research site
Related Studies
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Miami, Florida
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPHASE1/PHASE2 · Recruiting · Turning Point Therapeutics, Inc. · Los Angeles, California
- UPLYFT For Lymphoma SurvivorsRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts